Recent Updates — PYXS
Pyxis Oncology reported a net loss of $20.0 million, or ($0.24) per share, for the quarter ended September 30, 2026, compared to a $22.0 million loss in the prior-year period. Research and development expenses decreased to $16.6 million from $17.8 million, while general and administrative expenses fell to $4.0 million from $5.7 million. The company holds approximately $57.0 million in cash and investments as of quarter-end, supplemented by net proceeds from a recent public offering that generated roughly $110.0 million in upfront gross proceeds. Pyxis Oncology is a clinical-stage biopharmaceutical company developing next-generation therapeutics for difficult-to-treat cancers.
Pyxis Oncology completed an underwritten public offering on October 1, 2026, raising approximately $102.8 million in net proceeds after deducting underwriting discounts and estimated expenses. The company issued 36,047,919 shares of common stock and pre-funded warrants for 1,883,121 additional shares, each accompanied by common warrants to purchase up to 49,310,352 shares at an exercise price of $3.50. The offering was priced at $2.90 per share unit and $2.899 per pre-funded warrant unit. Proceeds will fund the Phase 3 Headliner trial for micvotabart pelidotin (MICVO) in second-line head and neck squamous cell carcinoma, extending the cash runway into the first half of 2028. The company must obtain stockholder approval to increase authorized shares before the warrants become exercisable. Pyxis Oncology is a clinical-stage biotechnology company developing targeted therapies for cancer.
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers, announced updated data from its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. The data cutoff was August 18, 2026, for the 5.4 mg/kg dose cap population. MICVO demonstrated a confirmed objective response rate of 36% and a disease control rate of 94%. Median progression-free survival was 6.2 months, with a 12-month overall survival probability of 79%. No new safety signals were observed, though peripheral neuropathy occurred in 40% of patients. The company plans to initiate a pivotal Phase 3 trial in mid-2027.
Pyxis Oncology appointed Thomas Civik as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, following his tenure as Interim CEO since February 2026. The company granted Mr. Civik a $100,000 sign-on bonus and a nonqualified stock option to purchase 2,503,050 shares with standard four-year vesting. John Flavin transitioned from Chairman to Lead Independent Director and Compensation Committee Chair. Concurrently, Dr. Santhosh Palani resigned from the Board for personal reasons, reducing board size to seven members; his unvested equity awards were fully accelerated. Pyxis Oncology is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers.
Pyxis Oncology reported a net loss of $25.3 million ($0.40 per share) for the quarter ended June 30, 2026, compared to a $18.4 million loss in the prior year period. The company completed a private placement financing on July 2, 2026, securing approximately $50 million in upfront gross proceeds and up to an additional $64 million if warrants are exercised. This capital, combined with existing cash reserves of $34.5 million as of June 30, extends the company's cash runway into the second quarter of 2027. Clinical updates include expected data releases for MICVO monotherapy in Fall 2026 and combination therapy with pembrolizumab in Q4 2026. Pyxis Oncology is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers.
Pyxis Oncology, Inc. entered into a securities purchase agreement on June 30, 2026, for a private placement with institutional and accredited investors. The company will issue 19,600,153 shares of common stock at $2.551 per share and common warrants to purchase an equal number of shares at an exercise price of $3.289. The transaction is expected to generate approximately $50.0 million in gross upfront proceeds, with an additional $64.0 million possible upon warrant exercise. The proceeds are intended to extend the company's cash runway into the second quarter of 2027 and support the MICVO clinical program. Wells Fargo Securities, LLC is acting as the placement agent. Pyxis Oncology, Inc. is a biotechnology company developing oncology therapeutics.